Platelet count ? , cells/mm ( x /L) Platelet count > , cells/dL ( x e/L) Platelet count >= , cells/mm^ ( x ^/L) at least weeks prior to screening unless attributable to disease; platelet count >= , cells/mm^ is permissible if due to disease Platelet count ? , cells/mm Platelet count > , cells/mm^ ( x ^/L) Platelet count > , cells/mm^ Platelet count > , cells/mm^ ( x ^/L), if thrombocytopenia is due to bone marrow involvement platelet count must be >= , cells/mm^ Platelet count ? , cells/mm ( x /L) (without required transfusions during the days prior to initiation of therapy) Platelet count ? , cells/mm^ Platelet count >= , cells/mm^ ( x ^/L) must be met during screening (within days) and also prior to study drug administration on cycle day Platelet count > , cells/mm^ ( x ^/L) Patients with lack of count recovery as defined by ANC > cells/mm^, non-transfused platelet count > , K/mm^ Platelet >= , cells/mm^ Platelet count > , cells/mm^ ( x ^/L) Platelet count > , cells/mm^ Platelet count > , cells/mm^ ( x ^/L) Platelet count >= , cells/mm^ if marrow plasmacytosis < %; platelet count >= , cells/mm^ if marrow plasmacytosis >= % Platelet count >= , cells/mm^ prior to biopsy; platelets >= , cells/mm^ prior to infusion Platelet count >= , cells/mm^ or >= bil/L Within weeks of enrollment: Platelet count, >= , cells/mm^ Platelet >= , cells/mm^ Platelet count >= , cells/mm^ Platelet count >= , cells/mm^ or >= bil/L Platelet count >= , cells/mm^ ( x ^/L), at screening Patients should have adequate bone marrow function defined as an absolute peripheral granulocyte count (AGC) of >/= cells/mm and platelet count of >/= , cells/mm; Platelet count < , cells/mm. Platelet count < , cells/mm Hematology: ANC > cells/mm, platelet count >, cells/mm and Hemoglobin > gm/L Platelet count ?, cells/mm Platelet count ?, cells/mm Platelet count ? , cells/mm^ ? weeks Platelets >= , cells/mm^ if marrow plasmacytosis < % OR platelet count >= , cells/mm^ if marrow plasmacytosis >= % Platelet count > , cells/mm^ Platelet count >= , cells/mm^ For RCC, platelet count ?, cells/mm Untransfused platelet count < , cells/?L Platelet count ? , cells/mm Platelet count > , cells/mm^ Platelet count ? , cells/dL ( x /L) Adequate baseline CBC, renal and hepatic function. Parameters described as WBC> cells/mm^, ANC>, cells/mm^, hemoglobin>.g/dL, and platelet count >, cells/mm^ Platelet count >= , cells/mm^ Platelet count >= , cells/mm^ Platelet count < x/L (< , cells/mm) Platelet count > , cells/mm^ ( x ^/L), if thrombocytopenia is due to bone marrow involvement platelet count must be , cells/mm^ Platelet count >= , cells/mm^ or >= bil/L Platelet count >= , cells/mm^ or >= bil/L Platelet count >= , cells/mm^ or >= bil/L Within one week of study entry: Platelet count at least , cells/mm^ Platelet count at least , cells/mm^ Adequate hematologic status ANC >=,cells/mm Platelet Count >= ,cells/mm Hemoglobin >=.g/dL Platelet count > , cells/mm, hemoglobin > g/dL, absolute neutrophil count > , cells/mm Adequate hematologic status ANC >=,cells/mm Platelet Count >=,cells/mm Hemoglobin >=.g/dL Platelet count >= x ^ cells/L Platelet count ? , cells/mm Platelet count >, cells/mm ( x /L) Platelet count ? , ( /L) cells/mm; Platelet count > , cells/dL ( x /L) Platelet count >= , cells/mm without transfusion or growth factor requirement Platelet count >= , cells/mm^ Platelet >= , cells/mm^, +/- days from date of ICF signing Platelet count ? , cells/mm ( x /L) or ? , cells/mm ( x /L) if secondary to bone marrow involvement by disease. Platelet count at least , cells/mm^ Platelet count ? , cells/mm Platelet count . cells/mm ( x /L) Platelet count >, cells/mm Platelet count >= , cells/mm^ Hematology: ANC > cells/mm, platelet count > , cells/mm and Hemoglobin > g/dL Platelet count >= , cells/mm^ Untransfused platelet count < , cells/L ( x ^/L) Platelet count >= , cells/mm^ Required prior to infusion of ATLCAR.CD cells: Platelet count >= , cells/mm^ without transfusion over preceding days Platelet dysfunction or platelet count < x cells/mm Platelet count > , cells/mm^*